...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American journal of therapeutics >American pain society pain questionnaire and other pain measures in the assessment of osteoarthritis pain: a pooled analysis of three celecoxib pivotal studies.
【24h】

American pain society pain questionnaire and other pain measures in the assessment of osteoarthritis pain: a pooled analysis of three celecoxib pivotal studies.

机译：美国疼痛学会疼痛调查表和其他疼痛评估方法，用于评估骨关节炎疼痛：三项塞来昔布关键研究的汇总分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of this study was to evaluate the utility of the American Pain Society (APS) questionnaire in the assessment of osteoarthritis (OA) pain and to determine the onset of action of celecoxib in the treatment of acute flare pain in patients with OA of the knee or hip. Pooled data from three pivotal, randomized, double-blind, placebo-controlled, 12-week trials of patients with OA who exhibited a flare of disease activity after withdrawal of nonsteroidal anti-inflammatory drug or analgesic therapy were evaluated. Patients completed the APS Pain Measure Questionnaire, which evaluates pain intensity and quality of life, at baseline and daily for the first 7 days of therapy. In addition, patients underwent a range of standard OA assessments to evaluate the analgesic efficacy of celecoxib up to 12 weeks. Three thousand two hundred fifty-eight patients were enrolled in the three studies, of whom 2041 completed the APS questionnaire (1010 received celecoxib, 513 received naproxen, and 518 received placebo).Within the first 24 hours, celecoxib at a dose of 200 or 400 mg/d significantly reduced the amount of acute pain experienced compared with placebo for four of the five measures, and statistical significance for the remaining parameter, "pain in the last 24 hours," was achieved on day 2. Celecoxib at a dose of 200 to 400 mg/d provided similar efficacy to naproxen at a dose of 1000 mg/d. The pain relief observed with celecoxib was maintained for the APS evaluation period. Long-term efficacy assessments showed the efficacy of 200 mg/d of celecoxib to be continuous and maintained for at least the 12 weeks of the study and that it was equivalent to 400 mg/d of celecoxib and 1000 mg/d of naproxen. This study demonstrates that the APS questionnaire is a useful measure of pain and therapeutic response in OA. Celecoxib furthermore seems to be an effective acute and chronic analgesic in OA.
机译：这项研究的目的是评估美国疼痛学会（APS）调查表在评估骨关节炎（OA）疼痛中的效用，并确定塞来昔布在治疗OA急性发作性疼痛中的作用开始。膝盖或臀部。对三项关键性，随机，双盲，安慰剂对照，为期12周的OA患者试验的汇总数据进行了评估，这些试验在停用非甾体类抗炎药或镇痛药后表现出疾病发作。患者完成了APS疼痛测量问卷，该问卷在治疗的前7天每天和基线时评估疼痛强度和生活质量。此外，患者接受了一系列标准的OA评估，以评估塞来昔布长达12周的镇痛效果。在这三项研究中招募了238位患者，其中2041位完成了APS问卷调查（1010位接受塞来昔布，513位接受萘普生，518位接受安慰剂）。在最初的24小时内，塞来昔布的剂量为200或与安慰剂相比，五种措施中的四种在400 mg / d的剂量下均显着减少了所经历的急性疼痛程度，并且在第2天就达到了剩余参数“最近24小时内的疼痛”的统计学意义。 200至400 mg / d的剂量在1000 mg / d时可提供与萘普生相似的功效。在APS评估期间，维持用塞来昔布观察到的疼痛缓解。长期疗效评估表明，持续200 mg / d塞来昔布的疗效持续至少12周，并且相当于400 mg / d塞来昔布和1000 mg / d萘普生。这项研究表明，APS问卷是对OA疼痛和治疗反应的有用度量。此外，塞来昔布似乎是OA的一种有效的急性和慢性镇痛药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号